Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Benjamin Nykamp

Dermatology Ada, MI Medical Doctor

NPI 1700984390 CMS profile 168022

6741 Fulton St E, Suite 204, Ada, MI 49301

Open in the dashboard

General payments

$3,391

199 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Benjamin Nykamp of Ada, MI is reported in the CMS Open Payments database as having received $3,391 across 199 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $559 33
2020 General $1,081 67
2019 General $1,751 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Nykamp
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Benjamin Nykamp were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Benjamin Nykamp Dermatology median Middle half National median
2019 $1,751 $454 $129–$1,240 $163
2020 $1,081 $235 $81–$756 $114
2021 $559 $377 $108–$1,108 $132
2022 $0 $514 $143–$1,391 $149
2023 $0 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Novartis Pharmaceuticals Corporation $848 65 payments
  2. AbbVie, Inc. $601 26 payments
  3. Janssen Biotech, Inc. $399 31 payments
  4. Amgen Inc. $308 12 payments
  5. Janssen Scientific Affairs, LLC $298 3 payments
  6. Lilly USA, LLC $285 18 payments
  7. Celgene Corporation $281 27 payments
  8. Genzyme Corporation $206 7 payments
  9. UCB, Inc. $102 6 payments
  10. Sun Pharmaceutical Industries Inc. $29 2 payments
  11. Other $33 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $3,292 198 payments
  2. Education $99 1 payment
Products named General payments · program years 2019–2021
  1. TREMFYA $627 29 payments
  2. HUMIRA $493 23 payments
  3. COSENTYX Immunology $462 38 payments
  4. COSENTYX Dermatology $386 27 payments
  5. SKYRIZI $351 19 payments
  6. Otezla Inflammation $308 12 payments
  7. TALTZ $285 18 payments
  8. Otezla Dermatology $281 27 payments
  9. DUPIXENT $120 5 payments
  10. Cimzia $102 6 payments
  11. Other $429 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

199 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record